Jeffrey Modell Foundation opens new center for primary immunodeficiency

The Jeffrey Modell Foundation today announced the opening of a new center at Johns Hopkins Children's Center dedicated to the early diagnosis and appropriate treatment of children with primary immunodeficiency (PI), a group of potentially fatal conditions in which the immune system malfunctions or is missing.

The newly-established Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, located on the Hopkin's Children's campus, will enhance the resources that are currently available to patients with PI in the greater Baltimore area. The center will also conduct research to explore the basis of these rare, genetic diseases.

"There is a large, under-diagnosed population of children and young adults suffering with these debilitating diseases and keeping them from enjoying a full life," said Vicki Modell, Co-Founder of the Jeffrey Modell Foundation. "Their illness interrupts their activities, detours their plans, and shatters their dreams. We are honored that a world renowned institution such as Johns Hopkins has joined our network of more than 100 Centers around the world."

Funding for the center was given to the Jeffrey Modell Foundation by Talecris Biotherapeutics, a biotechnology company that produces plasma-based protein therapies to treat PI and other rare disorders (  

"The Jeffrey Modell Foundation's unwavering dedication to the early diagnosis and treatment of PI is evident through its many successful endeavors, the most recent of which is the expansion of diagnostic services and outreach at Johns Hopkins," said Lawrence D. Stern, Chairman and CEO of Talecris Biotherapeutics. "Talecris' collaboration with the Jeffrey Modell Foundation and Johns Hopkins demonstrates our ongoing commitment to improving the lives of those with PI."


Jeffrey Modell Foundation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
How national programs leveraged PEPFAR-supported laboratory resources for SARS-CoV-2 testing during the COVID-19 pandemic